TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Study Details
Study Description
Brief Summary
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug.
NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact TAPUR@asco.org, or if a patient, your nearest participating TAPUR site (see participating centers).
Results in publication or poster presentation format are posted as they become available for individual cohorts at www.tapur.org/news. The results may be accessed at any time. All results will be made available on clinicaltrials.gov at the end of the study. Indexing of available results on PubMed is in progress.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 2 |
Detailed Description
The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a non-randomized clinical trial that aims to describe the safety and efficacy of commercially available, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic variant. TAPUR will study Food and Drug Administration (FDA)-approved targeted therapies that are contributed by collaborating pharmaceutical companies, catalogue the choice of molecular profiling test by clinical oncologists and develop hypotheses for additional clinical trials.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Other: Group 3 (ALK, ROS1, MET) Participants receive crizotinib - dosage, frequency and duration per label; acceptable genomic matches include ALK fusion or mutation, ROS1 fusion, MET amplification or mutation, MET exon 14 alteration, RON amplification or mutation |
Drug: Crizotinib
drug
Other Names:
|
Other: Group 4 (CDKN2A, CDK4, CDK6) Participants receive palbociclib - dosage, frequency and duration per label; acceptable genomic matches include CDKN2A loss or mutation, CDK4, CDK6 amplifications |
Drug: Palbociclib
drug
Other Names:
|
Other: Group 5 (CSF1R,PDGFR,VEGFR) Participants receive sunitinib - dosage, frequency and duration per label; acceptable genomic matches include CSF1R, PDGFR, VEGFR1/2/3, KIT, FLT-3, RET, FGFR1/2/3, VHL amplifications or mutations |
Drug: Sunitinib
drug
Other Names:
|
Other: Group 6 (mTOR, TSC) Participants receive temsirolimus - dosage, frequency and duration per label; acceptable genomic matches include mTOR, TSC1/2, AKT1 mutations |
Drug: Temsirolimus
drug
Other Names:
|
Other: Group 8 (ERBB2) Participants receive trastuzumab and pertuzumab - dosage, frequency and duration per label; acceptable genomic matches include ERBB2 amplification or overexpression, and specific ERBB2 mutations |
Drug: Trastuzumab and Pertuzumab
drug
Other Names:
|
Other: Group 9 (BRAF V600E/D/K/R) Participants receive vemurafenib and cobimetinib - dosage, frequency and duration per label; acceptable genomic matches include BRAF V600E/D/K/R mutations |
Drug: Vemurafenib and Cobimetinib
drug
Other Names:
|
Other: Group 13 (RET,VEGFR1/2/3,KIT,PDGFRβ,RAF-1,BRAF) Participants receive regorafenib - dosage, frequency and duration per label; acceptable genomic matches include RET, VEGFR1/2/3, KIT, PDGFRβ, RAF-1, BRAF mutations or amplifications |
Drug: Regorafenib
drug
Other Names:
|
Other: Group 14 (BRCA1/2; ATM) Participants receive olaparib - dosage, frequency and duration per label; acceptable genomic matches include germline or somatic BRCA1/2 inactivating mutations; ATM mutations or deletions |
Drug: Olaparib
drug
Other Names:
|
Other: Group 15 (POLE, POLD1) Participants receive pembrolizumab - dosage, frequency and duration per label; acceptable genomic matches include specific POLE and POLD1 mutations |
Drug: Pembrolizumab
drug
Other Names:
|
Other: Group 16 (MSI-H, high mutational load and others) Participants receive nivolumab and ipilimumab - dosage, frequency and duration per label; acceptable genomic matches include MSI high status, high tumor mutational burden, MLH1, MSH2/6, PMS2, EPCAM mutations, specific POLE or POLD1 mutations, BRCA1/2, ATM, MSH3, PMS1, MLH3, EXO1, RFC1/2/3/4/5, PCNA, RPA1/2/3/4, and SSBP1 loss of function mutations |
Drug: Nivolumab and Ipilimumab
drug
Other Names:
|
Other: Group 17 (CDKN2A, CDK4, CDK6) Participants receive abemaciclib - dosage, frequency and duration per label; acceptable genomic matches include CDKN2A loss or mutation, CDK4, CDK6 amplifications |
Drug: Abemaciclib
drug
Other Names:
|
Other: Group 18 (NRG1) Participants receive afatinib - dosage, frequency and duration per label; acceptable genomic matches include NRG1 fusions |
Drug: Afatinib
drug
Other Names:
|
Other: Group 19 (BRCA1/2, PALB2) Participants receive talazoparib - dosage, frequency and duration per label; acceptable genomic matches include germline or somatic BRCA1/2 and PALB2 mutations |
Drug: Talazoparib
drug
Other Names:
|
Other: Group 20 (ERBB2) Participants receive atezolizumab plus PHESGO - dosage, frequency and duration per label; acceptable genomic matches include ERBB2 amplification or overexpression |
Drug: Atezolizumab and PHESGO
drug
Other Names:
|
Other: Group 21 (BRCA1/2, PALB2, ATM, and others) Participants receive atezolizumab plus talazoparib - dosage, frequency and duration per label; acceptable genomic matches include germline or somatic mutations in BRCA1/2, PALB2, ATM, ATR, CHEK2, FANCA, RAD51C, NBN, MLH1, MRE11A, CDK12; positive genomic instability score reported on the Myriad MyChoice CDx test; or Genomic Loss of Heterozygosity (LOH) Score above threshold as reported on a FoundationOne CDx test |
Drug: Atezolizumab and Talazoparib
drug
Other Names:
|
Other: Group 22 (ROS1 fusion) Participants receive entrectinib - dosage, frequency and duration per label; acceptable genomic matches include any ROS1 fusion |
Drug: Entrectinib
drug
Other Names:
|
Other: Group 23 (NTRK amplification) Participants receive larotrectinib - dosage, frequency and duration per label; acceptable genomic matches include NTRK1/2/3 amplification |
Drug: Larotrectinib
drug
Other Names:
|
Other: Group 24 (ERBB2) Participants receive tucatinib plus trastuzumab SC - dosage, frequency and duration per label; acceptable genomic matches include ERBB2 amplification or overexpression, and specific ERBB2 mutations |
Drug: Tucatinib plus Trastuzumab Subcutaneous (SC)
drug
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Objective Response Rate defined as % of participants in a cohort with complete or partial response or with stable disease according to standard response criteria [Assessed at 16 weeks of treatment]
Each cohort includes participants with the same tumor type, genomic variant and study drug. For solid tumors, the Response Evaluation Criteria for Solid Tumors (RECIST) criteria will be used, for non-Hodgkin Lymphoma, the Lugano Criteria will be used, and for multiple myeloma, the International Uniform Response Criteria for Multiple Myeloma will be used.
Secondary Outcome Measures
- Overall survival (OS) [Duration of survival from registration on study until death from any cause, assessed throughout end of study, up to 3 years]
OS will be estimated using the Kaplan-Meier method
Eligibility Criteria
Criteria
Inclusion Criteria:
-
12 years of age or older (*Restrictions apply. Not all therapies are available for patients <18)
-
Histologically-proven locally advanced or metastatic solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma who is no longer benefiting from standard anti-cancer treatment or for whom, in the opinion of the treating physician, no such treatment is available or indicated
-
Performance status 0-2 (Per Eastern Cooperative Oncology Group (ECOG) criteria)
-
Patients must have acceptable organ function as defined below. However, as noted above, drug-specific inclusion/exclusion criteria specified in the protocol appendix for each agent will take precedence for this and all inclusion criteria:
-
Absolute neutrophil count ≥ 1.5 x 106/µl
-
Hemoglobin > 9.0 g/dl
-
Platelets > 75,000/µl
-
Total bilirubin < 2.0 mg/ dl, except in patients with Gilbert's Syndrome
-
Aspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT) serum glutamic-pyruvic transaminase (SGPT) < 2.5 x institutional upper limit of normal (ULN) (or < 5 x ULN in patients with known hepatic metastases)
-
Serum creatinine ≤ 1.5 × ULN or calculated or measured creatinine clearance ≥ 50 mL/min/1.73 m2
-
Patients must have disease that can be objectively measured by physicial or radiographic exam or evaluable disease (per RECIST v1.1 for solid tumor, Lugano criteria for non Hodgkin lymphoma or International Myeloma Working Group criteria for multiple myeloma), defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as ≥20 mm with conventional techniques or as ≥10 mm with spiral computed tomography (CT) scan, Magnetic Resonance Imaging (MRI), or a subcutaneous or superficial lesion that can be measured with calipers by clinical exam. For lymph nodes, the short axis must be ≥15 mm. Patients who have assessable disease by physical or radiographic examination but do not meet these definitions of measurable disease are eligible and will be considered to have evaluable disease. Patient's whose disease cannot be objectively measured by physical or radiographic examination (e.g., elevated serum tumor marker only, bone-only disease without an identifiable soft tissue component, or patients with only assessable non-measurable disease) are NOT eligible.
-
Results must be available from a genomic test or immunohistochemistry (IHC) test for protein expression performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified and College of American Pathologists (CAP)-accredited or New York State accredited (for labs offering services to residents of NY) laboratory. Labs that have registered the test with the NIH Genetic Testing Registry or that provide a report that has been designated as optimized for TAPUR participation are preferred, but not required. The genomic or IHC test used to qualify a patient for participation in TAPUR may have been performed on any specimen of the patient's tumor obtained at any point during the patient's care at the discretion of the patient's treating physician. Genomic assays performed on cell-free DNA in plasma ("liquid biopsies") will also be acceptable if the genomic analysis is performed in a laboratory that meets the criteria described above.
-
Ability to understand and the willingness to sign a written informed consent/assent document.
-
Have a tumor genomic profile for which single agent treatment with one of the FDA approved targeted anti-cancer drugs included in this study has potential clinical benefit based on the criteria described in protocol.
-
For orally administered drugs, the patient must be able to swallow and tolerate oral medication and must have no known malabsorption syndrome.
-
Because of the risks of drug treatment to the developing fetus, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation, and for four months following completion of study therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study or if she is the partner of a male participant in this study and becomes pregnant while he is participating in this study, she should inform her or her partner's treating physician immediately as well as her obstetrician. Female study patients who become pregnant must immediately discontinue treatment with any study therapy. Male patients should avoid impregnating a female partner. Male study patients, even if surgically sterilized, (i.e. post-vasectomy) must agree to one of the following: practice effective barrier contraception during the entire study treatment period and for a specified amount of time the last dose of study drug, or completely abstain from sexual intercourse.
Note: TAPUR does not explicitly exclude any type of solid tumor, but the patient must have measurable and evaluable disease per RECIST v1.1.
Exclusion Criteria:
-
Patients whose disease is not measurable or cannot be assessed by radiographic imaging or physical examination (e.g., elevated serum tumor marker only) are not eligible
-
Patients with primary brain tumors or leptomeningeal metastases are excluded.
-
Patients with previously treated brain metastases are eligible, provided that the patient has not experienced a seizure or had a clinically significant change in neurological status within the 3 months prior to registration. All patients with previously treated brain metastases must be clinically stable for at least 1 month after completion of treatment and off steroid treatment for one month prior to study enrollment.
-
Patients with known progressive brain metastases are eligible but additional eligibility criteria apply.
Note: there are additional exclusion criteria that may apply
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | University of Alabama at Birmingham Comprehensive Cancer Center | Birmingham | Alabama | United States | 35294 |
2 | Cancer Treatment Centers of America-Phoenix | Phoenix | Arizona | United States | 85338 |
3 | Sutter Auburn | Auburn | California | United States | 95602 |
4 | Sutter Alta Bates | Berkeley | California | United States | 94705 |
5 | The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate | Los Angeles | California | United States | 90025 |
6 | Kaiser Permanente - Oakland Medical Center | Oakland | California | United States | 94611 |
7 | Sutter Palo Alto Medical Foundation: Palo Alto | Palo Alto | California | United States | 94301 |
8 | Kaiser Permanente - Roseville Medical Center | Roseville | California | United States | 95661 |
9 | Sutter Roseville | Roseville | California | United States | 95661 |
10 | Kaiser Permanente - Sacramento Medical Center | Sacramento | California | United States | 95814 |
11 | Sutter Sacramento | Sacramento | California | United States | 95816 |
12 | Kaiser Permanente - South San Francisco Medical Center | San Francisco | California | United States | 94080 |
13 | California Pacific Medical Center Research Institute | San Francisco | California | United States | 94115 |
14 | Kaiser Permanente - San Francisco Medical Center | San Francisco | California | United States | 94115 |
15 | Sutter Cancer Research Consortium | San Francisco | California | United States | 94115 |
16 | Kaiser Permanente - San Jose Medical Center | San Jose | California | United States | 95119 |
17 | Kaiser Permanente - San Leandro Medical Center | San Leandro | California | United States | 94577 |
18 | Kaiser Permanente - Santa Clara Medical Center | Santa Clara | California | United States | 95051 |
19 | Sutter Palo Alto Medical Foundation: Santa Cruz | Santa Cruz | California | United States | 95065 |
20 | Sutter Palo Alto Medical Foundation: Fremont | Santa Cruz | California | United States | 994538 |
21 | Sutter Palo Alto Medical Foundation: Sunnyvale | Sunnyvale | California | United States | 94086 |
22 | Kaiser Permanente - Vallejo Medical Center | Vallejo | California | United States | 94589 |
23 | Kaiser Permanente - Walnut Creek Medical Center | Walnut Creek | California | United States | 94596 |
24 | Saint Vincent's Medical Center (SVMC) | Bridgeport | Connecticut | United States | 06606 |
25 | Hartford Hospital | Hartford | Connecticut | United States | 06002 |
26 | Midstate Medical Center (MSMC) | Meriden | Connecticut | United States | 06451 |
27 | The Hospital of Central Connecticut (HOCC) Cancer Center | New Britain | Connecticut | United States | 06053 |
28 | William W. Backus Hospital | Norwich | Connecticut | United States | 06360 |
29 | Charlotte Hungerford | Torrington | Connecticut | United States | 06790 |
30 | Windham Hospital (WH) | Willimantic | Connecticut | United States | 06226 |
31 | Holy Cross Hospital | Fort Lauderdale | Florida | United States | 33308 |
32 | Florida Cancer Specialists South / Sarah Cannon Research Institute | Fort Myers | Florida | United States | 33901 |
33 | University of Florida Health | Gainesville | Florida | United States | 32610 |
34 | University of Miami Sylvester Comprehensive Cancer Center | Miami | Florida | United States | 33136 |
35 | Florida Cancer Specialists North / Sarah Cannon Research Institute | Saint Petersburg | Florida | United States | 33705 |
36 | Florida Cancer Specialists Panhandle / Sarah Cannon Research Institute | Tallahassee | Florida | United States | 32308 |
37 | Florida Cancer Specialists East / Sarah Cannon Research Institute | West Palm Beach | Florida | United States | 33401 |
38 | Cancer Treatment Centers of America - Atlanta | Atlanta | Georgia | United States | 30265 |
39 | Emory University Winship Cancer Institute | Atlanta | Georgia | United States | 30322 |
40 | Gynecologic Oncology and Surgical Specialists at the Lewis Cancer & Research Pavilion | Savannah | Georgia | United States | 31405 |
41 | Lewis Cancer & Research Pavilion at the Melanoma, Skin Cancer & Sarcoma Institute | Savannah | Georgia | United States | 31405 |
42 | Lewis Cancer & Research Pavilion | Savannah | Georgia | United States | 31405 |
43 | Summit Cancer Care | Savannah | Georgia | United States | 31405 |
44 | The Queen's Medical Center (The University of Texas MD Anderson Cancer Center) | Honolulu | Hawaii | United States | 96813 |
45 | Cancer Treatment Centers of America-Chicago | Chicago | Illinois | United States | 60099 |
46 | Community Health Network (The University of Texas MD Anderson Cancer Center) | Indianapolis | Indiana | United States | 46250 |
47 | Harold Alfond Center for Cancer Care | Augusta | Maine | United States | 04330 |
48 | Jackson Laboratory - Maine Cancer Genomics Initiative | Augusta | Maine | United States | 04330 |
49 | Waldo County General Hospital | Belfast | Maine | United States | 04915 |
50 | SMHC Cancer Care and Blood Disorders -Biddeford | Biddeford | Maine | United States | 04005 |
51 | Northern Light Cancer Care | Brewer | Maine | United States | 04412 |
52 | Raish Peavey Haskell Children's Cancer and Treatment Center | Brewer | Maine | United States | 04412 |
53 | MaineHealth Cancer Care -Brunswick | Brunswick | Maine | United States | 04011 |
54 | New England Cancer Specialist | Kennebunk | Maine | United States | 04043 |
55 | York Hopsital Oncology & Infusion Care in Kittery | Kittery | Maine | United States | 03904 |
56 | Stephens Memorial Hospital | Norway | Maine | United States | 04268 |
57 | Penobscot Bay Medical Center | Rockport | Maine | United States | 04856 |
58 | SMHC Cancer Care and Blood Disorders -Sandford | Sanford | Maine | United States | 04073 |
59 | Maine Children's Cancer Program | Scarborough | Maine | United States | 04074 |
60 | Maine Medical Partner's Women's Health | Scarborough | Maine | United States | 04074 |
61 | New England Cancer Specialist | Scarborough | Maine | United States | 04074 |
62 | MaineHealth Cancer Care -South Portland | South Portland | Maine | United States | 04106 |
63 | New England Cancer Specialist | Topsham | Maine | United States | 04086 |
64 | York Hospital Oncology & Infusion Care in Wells | Wells | Maine | United States | 04090 |
65 | York Hospital Oncology & Infusion Care in York | York | Maine | United States | 03909 |
66 | University of Michigan | Ann Arbor | Michigan | United States | 48109 |
67 | St. Joseph Mercy - Brighton | Brighton | Michigan | United States | 48114 |
68 | St. Joseph Mercy - Canton | Canton | Michigan | United States | 48188 |
69 | St. Joseph Mercy - Chelsea | Chelsea | Michigan | United States | 48118-1370 |
70 | Ascension St. John Hospital | Detroit | Michigan | United States | 48236 |
71 | Genesys Hurley Cancer Institute | Grand Blanc | Michigan | United States | 48439 |
72 | Cancer Research Consortium of West Michigan | Grand Rapids | Michigan | United States | 49503 |
73 | Ascension Borgess Cancer Center | Kalamazoo | Michigan | United States | 49009 |
74 | Sparrow Hospital | Lansing | Michigan | United States | 48912 |
75 | St. Mary Mercy Hospital | Livonia | Michigan | United States | 48154 |
76 | St. Joseph Mercy Hospital Oakland | Pontiac | Michigan | United States | 48341 |
77 | Ascension St. Mary's Hospital | Saginaw | Michigan | United States | 48601 |
78 | Michigan Cancer Research Consortium | Traverse City | Michigan | United States | 48341 |
79 | St. John Macomb Oakland Hospital | Warren | Michigan | United States | 48093 |
80 | University of Nebraska Medical Center | Omaha | Nebraska | United States | 68198 |
81 | NH Oncology - Hematology, PA | Concord | New Hampshire | United States | 03103 |
82 | Solinsky Center for Cancer Care | Manchester | New Hampshire | United States | 03103 |
83 | New England Cancer Specialist | Portsmouth | New Hampshire | United States | 03801 |
84 | Lovelace Medical Center - Saint Joseph Square | Albuquerque | New Mexico | United States | 87102 |
85 | Presbyterian Kaseman Hospital | Albuquerque | New Mexico | United States | 87110 |
86 | The University of New Mexico Comprehensive Cancer Center | Albuquerque | New Mexico | United States | 87131 |
87 | Memorial Medical Center | Las Cruces | New Mexico | United States | 88011 |
88 | Presbyterian Rust Medical Center | Rio Rancho | New Mexico | United States | 87124 |
89 | Northwell Health Monter Cancer Center | Lake Success | New York | United States | 11042 |
90 | Herbert Irving Comprehensive Cancer Center | New York | New York | United States | 10032 |
91 | Lineberger Comprehensive Cancer Center | Chapel Hill | North Carolina | United States | 27599 |
92 | Atrium Health's Levine Cancer Institute | Charlotte | North Carolina | United States | 28277 |
93 | Sanford Health- Bismarck | Bismarck | North Dakota | United States | 58501 |
94 | Sanford Health- Fargo | Fargo | North Dakota | United States | 58122 |
95 | University of Cincinnati Medical Center | Cincinnati | Ohio | United States | 45219 |
96 | Kettering Health | Kettering | Ohio | United States | 45429 |
97 | West Chester Hospital | West Chester | Ohio | United States | 45069 |
98 | Providence Health & Services | Portland | Oregon | United States | 97213 |
99 | Lehigh Valley Hospital | Allentown | Pennsylvania | United States | 18105 |
100 | Fox Chase Cancer Center | Philadelphia | Pennsylvania | United States | 19111 |
101 | SC Cancer Specialists at St. Joseph's/Candler Bluffton | Bluffton | South Carolina | United States | 29910 |
102 | St. Joseph's/Candler Smith | Bluffton | South Carolina | United States | 29910 |
103 | Summit Cancer Care at St. Josph's/Candler Bluffton | Bluffton | South Carolina | United States | 29910 |
104 | South Carolina Cancer Specialists | Hilton Head Island | South Carolina | United States | 29926 |
105 | Sanford Cancer Center Oncology Clinic and Pharmacy | Sioux Falls | South Dakota | United States | 57104 |
106 | Tennessee Oncology - Nashville / Sarah Cannon Research Institute | Nashville | Tennessee | United States | 37203 |
107 | The University of Texas MD Anderson Cancer Center | Houston | Texas | United States | 77030 |
108 | Intermountain Healthcare | Salt Lake City | Utah | United States | 84107 |
109 | Inova Schar Cancer Institute | Fairfax | Virginia | United States | 22042 |
110 | Swedish Cancer Institute | Seattle | Washington | United States | 98104 |
111 | Aurora Cancer Care - Burlington | Burlington | Wisconsin | United States | 53105 |
112 | Aurora Health Care - Germantown Health Center | Germantown | Wisconsin | United States | 53022 |
113 | Aurora Cancer Care - Grafton | Grafton | Wisconsin | United States | 53024 |
114 | Aurora BayCare Medical Center | Green Bay | Wisconsin | United States | 54311 |
115 | Aurora Cancer Care - Kenosha South | Kenosha | Wisconsin | United States | 53142 |
116 | Aurora Bay Area Medical Center | Marinette | Wisconsin | United States | 54143 |
117 | Aurora Cancer Care Milwaukee | Milwaukee | Wisconsin | United States | 53209 |
118 | Aurora St. Luke's Medical Center | Milwaukee | Wisconsin | United States | 53215 |
119 | Aurora Sinai Medical Center | Milwaukee | Wisconsin | United States | 53223 |
120 | Aurora West Allis Medical Center | Milwaukee | Wisconsin | United States | 53227 |
121 | Vince Lombardi Cancer Clinic - Oshkosh | Oshkosh | Wisconsin | United States | 54904 |
122 | Aurora Cancer Care - Racine | Racine | Wisconsin | United States | 53406 |
123 | Vince Lombardi Cancer Center | Sheboygan | Wisconsin | United States | 53081 |
124 | Aurora Medical Center in Summit | Summit | Wisconsin | United States | 53066 |
125 | Vince Lombardi Cancer Clinic - Two Rivers | Two Rivers | Wisconsin | United States | 54241 |
126 | Aurora Cancer Care - Milwaukee West | Wauwatosa | Wisconsin | United States | 53226 |
Sponsors and Collaborators
- American Society of Clinical Oncology
- AstraZeneca
- Bayer
- Bristol-Myers Squibb
- Eli Lilly and Company
- Genentech, Inc.
- Merck Sharp & Dohme LLC
- Pfizer
- Boehringer Ingelheim
- Seagen Inc.
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- Pro00014171